Melanoma genetics: The other side

Clinics in Dermatology

Volumn 31, Issue 2, 2013, Pages 148-155

  Bis, Sabina ^a   Tsao, Hensin ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; DASATINIB; EPHRIN RECEPTOR A2; GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN G SUBUNIT Q; GUANINE NUCLEOTIDE BINDING PROTEIN SUBUNIT ALPHA 11; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NILOTINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN AKT3; PROTEIN GRM3; PROTEIN H RAS; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN N RAS; PROTEIN TYROSINE KINASE; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

AKT3 GENE; ARTICLE; BRAF GENE; CANCER GENETICS; CANCER PROGNOSIS; CDK4 GENE; CDKN2A GENE; ERBB4 GENE; GENE; GENE MUTATION; GNA11 GENE; GNAQ GENE; GRIN2A GENE; GRM3 GENE; H RAS GENE; HDM2 GENE; HUMAN; KIT GENE; MAP2K1 GENE; MELANOMA SKIN CANCER; MITF GENE; NRAS GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PTEN GENE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; ONCOGENES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84874246085     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.003     Document Type: Article

References (60)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
3. Ross J.S., Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011, 136:527-539.
4. Lang J.M., Shennan M., Njauw J.C., et al. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds. J Invest Dermatol 2011, 131:480-486.
5. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
6. Antonescu C.R., Busam K.J., Francone T.D. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007, 121:257-264.
7. Beadling C., Jacobson-Dunlop E., Hodi F.S. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14:6821-6828.
8. Rivera R.S., Nagatsuka H., Gunduz M. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008, 452:27-32.
9. Torres-Cabala C.A., Wang W.L., Trent J., et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009, 22:1446-1456.
10. Nikolaou V.A., Stratigos A.J., Flaherty K.T., et al. Melanoma: new insights and new therapies. J Invest Dermatol 2012, 132:854-863.
11. Margaryan N.V., Strizzi L., Abbott D.E., et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009, 8:279-288.
12. Zhang G., Njauw C.N., Park J.M., et al. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008, 68:1691-1696.
13. Udayakumar D., Zhang G., Ji Z., et al. Epha2 is a critical oncogene in melanoma. Oncogene 2011, 30:4921-4929.
14. Prickett T.D., Agrawal N.S., Wei X., et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127-1132.
15. Rudloff U., Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010, 9:1487-1503.
16. Curtin J.A., Pinkel D., Bastian B.C. Absence of PDGFRA mutations in primary melanoma. J Invest Dermatol 2008, 128:488-489.
17. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
18. Shi H., Kong X., Ribas A., et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600E B-RAF inhibition. Cancer Res 2011, 71:5067-5074.
19. Takano T., Lin J.H., Arcuino G., et al. Glutamate release promotes growth of malignant gliomas. Nat Med 2001, 7:1010-1015.
20. Wei X., Walia V., Lin J.C., et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011, 43:442-446.
21. Prickett T.D., Wei X., Cardenas-Navia I., et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011, 43:1119-1126.
22. Bauer J., Curtin J.A., Pinkel D., et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007, 127:179-182.
23. Lee J.H., Choi J.W., Kim Y.S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776-784.
24. Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
25. Bastian B.C., LeBoit P.E., Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000, 157:967-972.
26. van Engen-van Grunsven A.C., van Dijk M.C., Ruiter D.J., et al. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. Am J Surg Pathol 2010, 34:1436-1441.
27. Van Dijk M.C., Bernsen M.R., Ruiter D.J. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005, 29:1145-1151.
28. Takata M., Lin J., Takayanagi S., et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol 2007, 156:1287-1294.
29. Da Forno P.D., Pringle J.H., Fletcher A., et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol 2009, 161:364-372.
30. Weber A., Hengge U.R., Urbanik D., et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 2003, 83:1771-1776.
31. Cruz F., Rubin B.P., Wilson D., et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003, 63:5761-5766.
32. Onken M.D., Worley L.A., Long M.D., et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008, 49:5230-5234.
33. Van Raamsdonk C.D., Bezrookove V., Green G., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
34. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363:2191-2199.
35. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
36. Fedorenko I.V., Paraiso K.H., Smalley K.S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011, 82:201-209.
37. Poulikakos P.I., Persaud Y., Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
38. Shi H., Moriceau G., Kong X., et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012, 3:724.
39. Lavoie H., Therrien M. Cancer: A drug-resistant duo. Nature 2011, 480:329-330.
40. Ko J.M., Fisher D.E. A new era: melanoma genetics and therapeutics. J Pathol 2011, 223:241-250.
41. Nikolaev S.I., Rimoldi D., Iseli C., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2011, 44:133-139.
42. Stahl J.M., Sharma A., Cheung M., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004, 64:7002-7010.
43. Bastian B.C., LeBoit P.E., Hamm H., et al. Chromosomalgains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998, 58:2170-2175.
44. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
45. Gast A., Scherer D., Chen B., et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010, 49:733-745.
46. de Snoo F.A., Hayward N.K. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005, 230:153-186.
47. Berwick M., Orlow I., Hummer A.J. The prevalence of CDKN2Agerm-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006, 15:1520-1525.
48. Bishop J.A., Wachsmuth R.C., Harland M., et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000, 114:28-33.
49. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007, 44:99-106.
50. Nikolaou V., Kang X., Stratigos A., et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011, 165:1219-1222.
51. Sini M.C., Manca A., Cossu A., et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 2008, 158:243-250.
52. Polsky D., Bastian B.C., Hazan C., et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001, 61:7642-7646.
53. Muthusamy V., Hobbs C., Nogueira C., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 45:447-454.
54. Box N.F., Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008, 21:525-533.
55. Hocker T., Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007, 28:578-588.
56. Ji Z., Njauw C.N., Taylor M., et al. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 2012, 132:356-364.
57. Haq R., Fisher D.E. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol. 2011, 29:3474-3482.
58. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
59. Cronin J.C., Wunderlich J., Loftus S.K., et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 2009, 22:435-444.
60. Yokoyama S., Woods S.L., Boyle G.M. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.